| Name | Title | Contact Details |
|---|
Strawn Arnold & Associates, Ltd.. is a premier provider of executive search to the healthcare industry. Our reputation has been built through executing searches for directors of governance boards, all levels of general management, as well as selected functional experts. Many of our Partners are recognized as "best in class" in their market segments. With nearly four decades of service and experience, Strawn Arnold & Associates, Ltd. is unparalleled in the depth of its knowledge and understanding of the healthcare market. Our firm stands for results, integrity and personal service, while providing access to business leaders at the highest level across the industry.
Kensey Nash Corporation is a medical device company known for product development and technology in the fields of resorbable biomaterials used in a variety of medical procedures and endovascular devices. The Company provides a range of products into
VNA is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.
As a non-profit business league, we`re funded by the healthcare industry to make the system work better for everyone. We do this work because we envision a future where providers can focus on delivering care. Health plans can focus on serving their customers. Purchasers can feel confident they`re getting the most value for their money. And where patients can ultimately get the best possible care at an affordable price. What brings us together at IHA is our passion to create a system where patients always receive the best possible care. We leave our egos at the door. We embrace the tough conversations. And we never lose sight of driving results. United by our values of Collaboration, Candor and Impact, our dedicated team works every day in support of high-quality, efficient care for all Californians. Our 40-member board of directors includes leaders from health plans, physician organizations, hospitals, health systems, purchasers, consumer groups, universities, and pharmaceutical and technology companies.